| Name | Title | Contact Details |
|---|
Mcnan Technologies Inc is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using our proprietary DIAMOND® artificial intelligence (AI) platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases. Kiromic is in the process of developing a multi-indication allogeneic CAR-T cell therapy that exploits the natural potency of Gamma Delta T-cells to target solid cancers. From our heritage as a cancer vaccine development company, Kiromic is focused on discovering, developing, and commercializing novel immuno-oncology applications through its robust product pipeline. Our pipeline development is leveraged through the Company`s proprietary target discovery engine called "DIAMOND," where big data science meets target identification to dramatically compress the man-years and billions of drug development dollars required to develop a live drug.
Targeting a better life for people with cancer is why we get up in the morning. It`s not enough to disrupt the progress of someone`s cancer; we want to keep cancer from disrupting someone`s life. That`s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. ImmunoGen is a leader in developing antibody-drug conjugates (ADCs). Our lead product candidate, mirvetuximab soravtansine, is a first-in-class folate receptor alpha (FRα)-targeting ADC with multiple studies underway in ovarian cancer. Our second pivotal program, IMGN632, is a CD123-targeting ADC being studied as a monotherapy in BPDCN and in combination in AML. Our earlier-stage assets in development are IMGC936, an ADAM9-targeting ADC in co-development with MacroGenics, and IMGN151, our next generation anti-folate receptor alpha ADC.
We are a precision medicines company looking to eliminate the “all comer” approach that is seen with today`s treatments for people with autoimmune disease. We are leveraging a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.
ZAGENO is on a mission to accelerate scientific innovation by streamlining biotech purchasing processes with its award-winning, first-of-its-kind e-commerce platform. With over 25 million product SKUs available from more than 5,000 unique product brands, ZAGENO makes online shopping for any research material convenient, efficient and reliable. The ZAGENO experience includes its Scientific Score, a best-in-class product rating system that offers unbiased, peer-reviewed ratings to support accurate purchasing decisions. Available on desktop, tablet, and mobile devices, ZAGENO makes biotech purchases easier than ever and is an ideal sales channel for suppliers and partners. Founded in 2015, the company is headquartered in the United States and has additional offices in Germany, and Poland.